These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23782588)

  • 1. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis.
    Zhang X; Chen YC; Fettner S; Rowell L; Gott T; Grimsey P; Unsworth A
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):620-30. PubMed ID: 23782588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
    Morcos PN; Zhang X; McIntyre C; Bittner B; Rowell L; Hussain Z
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):537-48. PubMed ID: 23547849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
    Zhang X; Georgy A; Rowell L
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):443-55. PubMed ID: 23547848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
    Ohta S; Tsuru T; Terao K; Mogi S; Suzaki M; Shono E; Ishida Y; Tarumi E; Imai M
    J Clin Pharmacol; 2014 Jan; 54(1):109-19. PubMed ID: 24115082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
    Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT
    J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
    Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
    Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
    Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
    Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Schmitt C; Kuhn B; Zhang X; Kivitz A; Grange S
    Int J Clin Pharmacol Ther; 2012 Mar; 50(3):218-23. PubMed ID: 22373834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
    Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients.
    Saito S; Suzuki K; Yoshimoto K; Kondo Y; Kikuchi J; Hanaoka H; Kaneko Y; Takeuchi T
    Clin Exp Rheumatol; 2023 Jul; 41(7):1451-1455. PubMed ID: 36533996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH; Gordan LN; Charu V; Wilhelm FE; Williams D; Xie J; Woodman RC
    Curr Med Res Opin; 2006 Jul; 22(7):1403-13. PubMed ID: 16834839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.